CATALOGO DEI PRODOTTI DELLA RICERCA

FRACASSO, Giulio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.435
EU - Europa 2.873
AS - Asia 1.016
SA - Sud America 23
AF - Africa 5
Continente sconosciuto - Info sul continente non disponibili 5
OC - Oceania 3
Totale 7.360
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.391
GB - Regno Unito 1.177
CN - Cina 839
IT - Italia 314
SE - Svezia 303
IE - Irlanda 292
FR - Francia 272
FI - Finlandia 183
DE - Germania 176
UA - Ucraina 68
VN - Vietnam 51
KR - Corea 36
CA - Canada 32
BE - Belgio 29
TR - Turchia 27
IN - India 13
IR - Iran 13
BR - Brasile 11
MX - Messico 11
NL - Olanda 8
RU - Federazione Russa 6
ES - Italia 5
PH - Filippine 5
PT - Portogallo 5
AR - Argentina 4
CH - Svizzera 4
LV - Lettonia 4
AU - Australia 3
AZ - Azerbaigian 3
BY - Bielorussia 3
CL - Cile 3
DK - Danimarca 3
EC - Ecuador 3
EU - Europa 3
GR - Grecia 3
HK - Hong Kong 3
ID - Indonesia 3
JP - Giappone 3
LU - Lussemburgo 3
PL - Polonia 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
CM - Camerun 2
HR - Croazia 2
KW - Kuwait 2
MA - Marocco 2
TH - Thailandia 2
TW - Taiwan 2
AL - Albania 1
BG - Bulgaria 1
BT - Bhutan 1
CZ - Repubblica Ceca 1
EG - Egitto 1
HU - Ungheria 1
IM - Isola di Man 1
IQ - Iraq 1
JO - Giordania 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LK - Sri Lanka 1
ME - Montenegro 1
NO - Norvegia 1
PA - Panama 1
PK - Pakistan 1
RO - Romania 1
RS - Serbia 1
SA - Arabia Saudita 1
SG - Singapore 1
SK - Slovacchia (Repubblica Slovacca) 1
TJ - Tagikistan 1
UY - Uruguay 1
VE - Venezuela 1
Totale 7.360
Salva come PNG Salva come JPEG
Città #
Southend 1.073
Chandler 644
Jacksonville 563
Woodbridge 408
Dublin 289
Ann Arbor 281
Houston 203
Ashburn 162
Beijing 162
Verona 134
Lawrence 106
Princeton 106
Wilmington 100
Jinan 88
Nanjing 76
Shenyang 64
New York 52
Hebei 49
Tianjin 45
Changsha 41
Sindelfingen 39
Dong Ket 35
Helsinki 33
Zhengzhou 33
Seoul 31
Brussels 29
Seattle 26
Haikou 25
Ningbo 25
Boardman 24
Milan 23
Redwood City 23
Jiaxing 22
Hangzhou 21
Taiyuan 21
Taizhou 21
Nanchang 19
Norwalk 18
Guangzhou 17
Lancaster 17
Fuzhou 16
Redmond 14
Los Angeles 13
Montréal 13
Bologna 11
San Francisco 11
Padova 9
Paris 8
Lanzhou 7
Phoenix 7
Tehran 7
Elora 5
Washington 5
Auburn Hills 4
Chicago 4
Dongguan 4
Fairfield 4
Kemerovo 4
Leawood 4
London 4
Tappahannock 4
Toronto 4
Ardabil 3
Baku 3
Belluno 3
Cambridge 3
Chions 3
Dearborn 3
Düsseldorf 3
Edinburgh 3
Falls Church 3
Guayaquil 3
Kochi 3
Luxembourg 3
Menlo Park 3
Montreal 3
Mumbai 3
Ome 3
Puxian 3
Riga 3
Salerno 3
Salt Lake City 3
Sejong 3
Shanghai 3
Tokyo 3
Trieste 3
Windsor 3
Almere Stad 2
Amsterdam 2
Augusta 2
Bari 2
Boston 2
Boydton 2
Buenos Aires 2
Cutrofiano 2
Dallas 2
Falkenstein 2
Frankfurt am Main 2
Fremont 2
Hanoi 2
Totale 5.411
Salva come PNG Salva come JPEG
Nome #
Anti PSMA immunotoxins activity against prostate cancer cell lines. 121
Feasibility of telomerase-specific adoptive T-cell therapy for B-cell chronic lymphocytic leukemia and solid malignancies 120
Filamin A-mediated interaction of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin regulates survival of advanced prostate cancer cells 110
Cooperation of Prostate Specific Membrane Antigen with beta 1 integrin promotes the survival of aggressive prostate cancer cells 110
Immunotoxins and other conjugates: preparation and general characteristics. 108
Anti-tumor effects of toxins targeted to the prostate specific membrane antigen. 105
Anti-PSMA-Immunotoxins: a new therapeutical strategy for selective targeting of toxins to prostate cancer cells. 102
Produzione e validazione preclinica di un anticorpo anti-PSMA per diagnostica ed immunotargeting 101
Plasmonic Nanostructures for SERRS Multiplexed Identification of Tumor-Associated Antigens 98
Protein Disulfide Isomerase and Thioredoxin Reductase: a ricin disulfide reducing system in the endoplasmic reticulum. 97
Apical transport and folding of prostate-specific membrane antigen occurs independent of glycan processing. 97
The prostate specific membrane antigen regulates the expression of IL-6 and CCL5 in prostate tumor cells by activating the MAPK pathways. 97
N-terminal deletion affetcs catalytic activity of saporin toxin. 96
Characterization of a new anti PSCA monoclonal antibody and scFv fragment for diagnosis and immunotherapy of prostate, pancreatic and bladder carcinoma. 95
A single-chain fragment against prostate specific membrane antigen as a tool to build theranostic reagents for prostate cancer 95
Reductive activation of ricin and ricin-A chain immunotoxins by Protein Disulfide Isomerase and Thioredoxin Reductase system. 94
EpCAM a possible target for immunotoxin treatments of PSMA positive and negative prostate cancer cells 94
The prostate specific membrane antigen regulates the expression of IL-6 and CCL-5 in prostate tumour cells by activating the MAPK pathways 94
A SERRS/MRI multimodal contrast agent based on naked Au nanoparticles functionalized with a Gd(iii) loaded PEG polymer for tumor imaging and localized hyperthermia 94
Ingegnerizzazione di un vettore per espressione di frammenti anticorpali (scFv) biotinilati in procarioti, purificazione ed analisi funzionale 93
Anticorpo monoclonale isolato o suo frammento legante l'antigene specifico di membrana della prostata, suoi coniugati e suoi usi 93
Targeted delivery of photosensitizers: efficacy and selectivity issues revealed by multifunctional ORMOSIL nanovectors in cellular systems 93
Induction of immunosuppressive functions and NF-κB by FLIP in monocytes 91
Reductive activation of ricin and ricin A-chain immunotoxins by protein disulfide isomerase and thioredoxin reductase. 89
Production of a biotinylated anti-PSMA single-chain antibody fragment (scFv) for imaging and radioimmunotherapy 89
Anti PSCA Monoclonal Antibody and scFv-Fragment for Immunotherapy of Prostate, Pancreatic and Bladder Carcinoma 88
Parallel optical read-out of micromechanical pillars applied to prostate specific membrane antigen detection 86
Investigation of Properties of Anti-Prostate Specific Membrane Antigen-targeted Gold Nanoparticles as Drug Carriers in Tumor Therapy 86
Prostate-specific membrane antigen associates already in the endoplasmic reticulum with lipid microdomains 86
Constitutive activation of p38 and ERK1/2 MAPKs in epithelial cells of myasthenic thymus leads to IL-6 and RANTES overexpression: effects on survival and migration of peripheral T and B cells. 85
Isolated monoclonal antibody or fragment thereof binding prostate specific membrane antigen, conjugates and uses thereof 84
Effect of therapeutic macromolecules in spheroids 83
Targeting human prostate cancer with (111) In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. 82
Prostate-specific membrane antigen (PSMA) associates early in the endoplasmic reticulum with lipid microdomains 82
Prostate-specific membrane antigen (PSMA) assembles a macromolecular complex regulating growth and survival of prostate cancer cells "in vitro" and correlating with progression "in vivo" 82
Self-potentiation of ligand-toxin conjugates containing ricin A chain fused with viral structures 82
Top-down synthesis of multifunctional iron oxide nanoparticles for macrophage labelling and manipulation 81
A dominant linear B-cell epitope of ricin A-chain is the target of a neutralizing antibody response in Hodgkin's lymphoma patients treated with an anti-CD25 immunotoxin 80
Anti-prostate specific membrane antigen targeted gold nanoparticles in tumor therapy and diagnosis 80
Biodistribution of In-111-labeled D2B IgG, F(ab’)2 and Fab fragments in nude mice bearing human prostate cancer xenografts 80
Generazione di nuovi anticorpi anti prostate stem cell antigen (PSCA) e loro caratterizzazione al fine di un futuro utilizzo nella terapia e nella diagnosi dei carcinomi prostatico, pancreatico e della vescica 79
Tumor Targeting with Guided Silica Nanopartilces for Prostate Cancer Therapy 79
Expression of myelin basic protein (MBP) epitopes in human non-neural cells revealed by two anti-MBP IgM monoclonal antibodies 78
Targeted Killing of Prostate Cancer Cells using Antibody-Drug conjugated Carbon Nanohorns 78
Identification of Ricin A chain HLA II-restricted epitopes by human T-cell clones. 75
Gangliosides act as onconeural antigens in paraneoplastic neuropathies. 75
PSMA-Specific CAR-Engineered T Cells Eradicate Disseminated Prostate Cancer in Preclinical Models 74
Discriminatory role of detergent-resistant membranes in the dimerization and endocytosis of prostate-specific membrane antigen 73
Magneto-Plasmonic Au-Fe alloy nanoparticles designed for multimodal SERS-MRI-CT imaging 73
Laser generated gold nanocorals with broadband plasmon absorption for photothermal applications 72
Liposomes derivatized with multimeric copies of KCCYSL peptide as targeting agents for HER-2-overexpressing tumor cells 71
Highly sensitive electrochemiluminescence detection of a prostate cancer biomarker 71
Pharmacokinetics of intrathecal transferrin-ricin A chain immunotoxins 70
Heterogeneous response of individual multicellular tumour spheroids to immunotoxins and ricin toxin 70
null 70
Cloning and characterisation of canine prostate-specific membrane antigen 70
The Filamin A-mediated cooperation of Prostate Specific Membrane Antigen (PSMA) with beta1 integrin promotes the survival of aggressive prostate cancer cells. 70
Pegylated silica nanoparticles: cytotoxicity and macrophage uptake 70
Prostate Specific Membrane Antigen (PSMA) associates with Filamin A, beta1 integrin, pp130CAS and pSrc thus regulating the activation of beta1 integrin and the survival of prostate cancer cells. 69
Therapeutic Efficacy of the Novel Stimuli-Sensitive Nano-Ferritins Containing Doxorubicin in a Head and Neck Cancer Model 69
Improved method for carbohydrate-deficient transferrin determination in human serum by capillary zone electrophoresis 67
An electrochemiluminescent-supramolecular approach to sarcosine detection for early diagnosis of prostate cancer. 67
Characterization of an In-111-labeled anti-PSMA antibody-photosensitizer conjugate for targeted photodynamic therapy of PSMA-expressing tumors 67
Prostate-specific membrane antigen routing to the cell surface implicates an early association step in the endoplasmic reticulum with lipid microdomains. 63
In vivo imaging of prostate cancer using an anti-PSMA scFv fragment as a probe 63
SERS IMAGING OF CANCER CELLS WITH ANTIBODY FUNCTIONALIZED GOLD NANOPARTICLES 62
null 61
Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen (PSMA) 58
Anti-PSMA CAR-engineered NK-92 Cells: An Off-the-shelf Cell Therapy for Prostate Cancer 58
Targeted Silica Nanoparticles for PhotoDynamic Therapy (PDT) 57
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors 57
Acute sarcomeric M-Line Disease associated with ATP synthase subunit α autoantibodies in ankylosing spondylitis 57
Different Glycoforms of Prostate-Specific Membrane Antigen are intracellularly transported through their Association with Distinct Detergent-Resistant Membranes 55
Characterization of In-111-labeled site-specifically conjugated anti-PSMA antibody-drug conjugates for treatment of PSMA-expressing tumors 55
Efficient AuFeOx Nanoclusters of Laser-Ablated Nanoparticles in Water for Cells Guiding and Surface-Enhanced Resonance Raman Scattering Imaging 54
Design and Evaluation of 223Ra-Labeled and Anti-{PSMA} Targeted {NaA} Nanozeolites for Prostate Cancer Therapy{ extemdash}Part {II}. Toxicity, Pharmacokinetics and Biodistribution 53
SERS labels for quantitative assays: application to the quantification of gold nanoparticles uptaken by macrophage cells 51
Ribosome-inactivating protein-containing conjugates for therapeutic use 49
Selective delivery of doxorubicin by novel stimuli-sensitive nano-ferritins overcomes tumor refractoriness 49
Immunology of RIPs and their Immunotoxins, in Ribosome-inactivating Proteins: Ricin and Related Proteins 48
Improved doxorubicin encapsulation and pharmacokinetics of ferritin-fusion protein nanocarriers bearing proline, serine, and alanine elements 48
Safe Core-Satellite Magneto-Plasmonic Nanostructures for Efficient Targeting and Photothermal Treatment of Tumor Cells 48
The presence of glutamate residues on the PAS sequence of the stimuli-sensitive nano-ferritin improves in vivo biodistribution and mitoxantrone encapsulation homogeneity 48
Simple and Rapid Non-Enzymatic Procedure Allows the Isolation of Structurally Preserved Connective Tissue Micro-Fragments Enriched with SVF 47
Effect of radiochemical modification on biodistribution of scFvD2B antibody fragment recognising prostate specific membrane antigen 46
SERRS Multiplexing with Multivalent Nanostructures for the Identification and Enumeration of Epithelial and Mesenchymal Cells 45
Polymer-coated silver-iron nanoparticles as efficient and biodegradable MRI contrast agents 45
Induction of in vitro and in vivo NK cell cytotoxicity using high-avidity immunoligands targeting prostate-specific membrane antigen in prostate carcinoma 44
New Tc-99m-radioimmunoconjugates for pancreatic carcinoma detection 44
Mitoxantrone-loaded nanoferritin slows tumor growth and improves the overall survival rate in a subcutaneous pancreatic cancer mouse model 43
Neutralization of NET-associated human ARG1 enhances cancer immunotherapy 42
Full preclinical validation of the 123I-labeled anti-PSMA antibody fragment ScFvD2B for prostate cancer imaging 42
Development of 177Lu-scFvD2B as a Potential Immunotheranostic Agent for Tumors Overexpressing the Prostate Specific Membrane Antigen 41
Engineered Human Nanoferritin Bearing the Drug Genz-644282 for Cancer Therapy 41
D2B antibody and its scFvD2B fragment in nanomedicine: promising tools in the theranostics of prostate cancer 41
Identification of ricin A-chain HLA class II-restricted epitopes by human T-cell clones 40
High activity and low toxicity of a novel CD71-targeting nanotherapeutic named The-0504 on preclinical models of several human aggressive tumors 40
Dual-modality image-guided surgery of prostate cancer with a radiolabeled fluorescent anti-PSMA monoclonal antibody 38
Development and characterization of a theranostic multimodal anti-PSMA targeting agent for imaging, surgical guidance, and targeted photodynamic therapy of PSMA-expressing tumors 38
Dual modality imaging of PSMA-expressing prostate cancer with a new radiolabeled anti-PSMA monoclonal antibody conjugated with IRDye800CW 37
Totale 7.188
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.968
article - articoli 16.830
book - libri 0
conference - conferenze 5.348
curatela - curatele 0
other - altro 0
patent - brevetti 421
selected - selezionate 0
volume - volumi 369
Totale 45.936
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/201945 0 0 0 0 0 0 0 0 0 0 22 23
2019/2020879 115 5 3 82 96 100 94 57 40 93 68 126
2020/2021905 68 145 61 95 113 101 21 66 52 20 97 66
2021/2022884 79 250 14 81 37 18 16 51 20 33 74 211
2022/20231.892 147 181 171 322 136 457 74 130 200 13 46 15
2023/2024727 43 85 91 94 109 122 35 55 12 79 2 0
Totale 7.471